CAESAREA, Israel , April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense® System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, 2022 in Vienna, Austria .
The ProSense® System is an effective Liquid Nitrogen (LN2) cryoablation solution, capable of creating large lethal zones for optimal tumor destruction with a rapid cooling rate and stable ultra-cold temperatures (-160°C +/- 10°C).
IceCure Industry Symposium: Liquid Nitrogen Based Cryoablation for Optimal Tumor Destruction
On April 25 , Professor Franco Orsi , MD, PhD of the European Institute of Oncology in Milan, Italy moderated the IceCure Industry Symposium: Liquid Nitrogen Based Cryoablation for Optimal Tumor Destruction. Professor Orsi provided a concise overview and rationale for performing cryoablation procedures followed by case studies from Dr. Yair Halpern of Bnei Zion Medical Center, Haifa, Israel on renal cancer cryoablation and from Dr. Ghizlane Touimi Benjelloun of CHU de Nîmes, France on cryoablation of adrenal gland and vertebral metastasis.
Scientific Presentation: Cryoablation of Low-Risk Breast Cancer An Update of the ICE3 Trial
Dr. Kenneth R. Tomkovich , Co-Primary Investigator of the ICE3 trial, presented promising interim data on cryoablation of small, low-risk breast cancers on April 26 . The interim results were originally published on April 29, 2021 and show almost 98% of patients who received ProSense® System cryoablation treatment are recurrence free, with one-third of patients having reached 5 years post-treatment. No significant device-related adverse events were reported with no scarring or change in shape and size of the breasts and 98% of doctors and 95% of patients reported satisfaction with the cosmetic results.
The ICE3 trial was designed to evaluate the safety and efficacy of breast cryoablation with IceCure's ProSense® System, enabling women older than 60 with low-risk early-stage breast cancers to benefit from a non-surgical treatment and avoid the associated surgical risks. The study, which enrolled 194 eligible patients, is the largest controlled multicenter clinical trial ever performed in the U.S. for LN2 based cryoablation of small, low-risk, early-stage malignant breast tumors as an alternative to surgery.
Dr, Tomkovich commented, "The inclusion of the ICE3 clinical trial interim results as part of the scientific program at ECIO 2022 represents a major milestone in women's health and more specifically breast cancer care. It presents an opportunity for interventional oncologists, in Europe and around the world, to use their expertise in image-guided tumor ablation to consider breast cancer cryoablation as a treatment now that the procedure is gaining wider acceptance as a viable non-surgical option for certain patients."
Cryoablation Hands-On Training with the ProSense® System
IceCure participated in ECIO's three hands-on cryoablation sessions. The IceCure team was joined by physicians well-experienced with the ProSense System to help guide participants during the sessions.
In addition to the exhibition and programming, IceCure was selected to attend ECIO's Faculty & Sponsor Dinner on April 24 . The event was a great opportunity for IceCure to meet with and build upon relationships with senior ECIO leadership and key opinion leaders in the field of interventional oncology.
"ECIO was an ideal forum to feature ProSense® to key opinion leaders and practitioners looking for a minimally invasive, image-guided system for oncological applications in both palliative and curative settings. As we expand regulatory approvals and distribution for ProSense® throughout the world, presenting data and providing hands-on training to a global audience is an important part of our efforts to establish ProSense® as a leading cryoablation system in the world and a safe, effective, and cost-efficient alternative to surgery," stated IceCure CEO Eyal Shamir .
Founded in 2006, Israel -based IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets ProSense®, an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed and sold worldwide for the indications cleared to-date by the U.S. Food and Drug Administration and approved in Europe with the CE Mark.
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses expanding regulatory approvals and distribution of ProSense and its efforts to establish ProSense® as the leading cryoablation system in the world. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 1, 2022 , which is available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Ronen Tsimerman Email: ronent@icecure-medical.com
Photo - https://mma.prnewswire.com/media/1805956/IceCure_Medical_at_ECIO_2022.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-medical-presents-ice3-breast-cancer-trial-interim-data-hosts-cryoablation-symposium--conducts-hands-on-prosense-training-sessions-at-the-european-conference-on-interventional-oncology-301534209.html
Homeowners beware. But don't panic, either.
On Wednesday, the Fed bumped up interest rates again, its third 75-basis point hike since June, and signaled that there could be two more such hikes by the end of this year. The conventional wisdom has the Fed acting properly, and aggressively, in an attempt to counter inflation raging at 40-year high levels. But conventional wisdom isn’t always right – and we can learn a lot by consulting the contrarians. Few top investors are more contrarian than Cathie Wood. The founder and manager of ARK Inv
KEY WORDS “I think we’re giving Powell too much praise. … The last two years are one of the biggest policy mistakes in the 110-year history of the Fed by staying so easy when everything was booming.
And what it means for your wealth-building options.
“We printed up too much money, and just thought the party would never end,” Icahn said, adding that with the Fed raising rates to fight inflation, "the party's over."
Warren Buffett’s long-term investment strategy has proven to be successful through virtually all market conditions over the past several decades – recession, high inflation and deflation. If there’s one thing that’s made Buffett one of the most successful investors in history, it’s his commitment to his strategy. A countless number of new investment techniques and algorithms have come and gone over the years, but Buffett has maintained his relatively simple strategy of picking solid companies an
The shipping company has developed a reputation as one of the best dividend stocks around
The hedge fund legend has spoken. Pay attention.
AT&T has been crushed this year, down more than 40% from its high. But now the stock nears a key area on the charts with a 7% dividend yield.
Novavax, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $NVAX performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
At a companywide all-hands meeting this week, Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) chief Sundar Pichai juggled tough questions from employees regarding cuts to travel and entertainment budgets, managing productivity, and potential layoffs. Employees questioned why Google is "nickel-and-diming employees" by cutting travel and swag budgets despite record profits and substantial cash reserves as it did after the pandemic. Pichai emphasized acting responsibly to tide through such critical sit
Workers questioned Google execs earlier this year after the company's 'Googlegeist' survey results came out.
Multiple insiders secured a larger position in Intel Corporation ( NASDAQ:INTC ) shares over the last 12 months. This...
As much as stocks are falling, moves in another financial market have even more profound implications for the global economy.
Companies like Microsoft, Chevron, and Becton Dickinson offer rising dividends and defensive growth in a tough market.
Shopify Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $SHOP performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.
Goldman finally decided to stop fighting the Fed and no longer sees the index finishing the year at 4300.
LONDON (Reuters) -Britain's new finance minister Kwasi Kwarteng unleashed historic tax cuts and huge increases in borrowing on Friday in an economic agenda that floored financial markets, sending sterling and British government bonds into freefall. Kwarteng scrapped the country's top rate of income tax, cancelled a planned rise in corporate taxes and for the first time put a price tag on the spending plans of Prime Minister Liz Truss, who wants to double Britain's rate of economic growth. Investors dumped short-dated British government bonds as fast as they could, with the cost of borrowing over five years seeing its biggest one-day rise since 1991, while the pound slumped more than 3% against the dollar to levels last seen 37 years ago.
Yahoo Finance reporter Alexandra Semenova breaks down Cathie Wood's decision to hand off her role as portfolio manager on two ETFs.
Shares of Carnival (NYSE: CCL), the world's biggest cruise line operator, were sliding today, in line with a broad market sell-off on fears of rising interest rates and a recession. For the third day in a row, stocks sank after the Federal Reserve raised the fed funds rate by 75 basis points, and Fed chair Jerome Powell said the central bank would continue to raise rates to rein in inflation, even if it means rising unemployment and an increased risk of a recession. The slide in the stock market over the last few days seems to reflect investors' view that the chances of a recession have increased, and that's bad news for travel stocks like Carnival, as travel, and vacations like cruising, are especially vulnerable.